Novartis

NVS · NYSE · USD

$141.00−0.04%−$0.05

Close · October 2, 2026

At a glance

Revenue growth: +9.57%; 2025 vs 2024
Net income growth: +17.11%; 2025 vs 2024
Net margin: 24.7%; 2024: 23.1%

Financial data

Amounts in millions of USD; per-share values in USD; shares in millions.

Income statement · Quarterly
Item	Q2 2026	Q1 2026	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023
Total revenue	14,951	13,524	13,860	14,358	14,836	13,620	13,558	13,172	12,872	12,120	11,776	12,092
Cost of revenue	3,678	3,438	3,542	3,535	3,322	3,227	3,312	3,234	3,173	3,096	2,570	3,117
Gross profit	11,273	10,086	10,318	10,823	11,514	10,393	10,246	9,938	9,699	9,024	9,206	8,975
Selling, general and administrative	3,231	3,137	3,436	3,304	3,442	3,058	3,499	3,134	3,091	2,840	3,416	3,091
Research and development	2,739	2,785	2,837	2,864	2,727	2,366	2,331	2,392	2,367	2,421	207	3,925
Operating income	5,176	4,122	3,855	4,585	5,011	4,704	5,306	3,634	3,985	3,389	6,061	1,666
EBIT	5,176	4,122	3,855	4,585	5,011	4,704	5,306	3,634	3,985	3,389	6,061	1,666
EBITDA	6,299	5,238	4,956	5,775	6,103	5,789	6,406	4,728	5,040	4,482	7,145	2,918
Interest expense	462	343	304	281	289	270	275	264	246	221	217	222
Pre-tax income	4,269	3,839	3,218	4,196	4,531	4,407	3,285	3,385	3,841	3,129	2,377	1,552
Income tax	1,012	683	814	266	507	798	465	200	595	441	-261	39.0
Net income	3,264	3,156	2,409	3,928	4,041	3,606	2,818	3,189	3,246	2,688	8,480	1,761
Net income to common shareholders	3,264	3,156	2,409	3,928	4,041	3,606	2,818	3,189	3,246	2,688	8,480	1,761
Basic EPS	1.71	1.65	1.26	2.04	2.07	1.83	1.42	1.58	1.60	1.32	4.14	0.85
Diluted EPS	1.71	1.65	1.25	2.02	2.06	1.82	1.41	1.57	1.59	1.31	4.11	0.85
Average shares (basic)	1,905	1,909	1,913	1,926	1,948	1,968	1,987	2,012	2,033	2,044	2,050	2,062
Average shares (diluted)	1,914	1,916	1,929	1,940	1,960	1,979	2,004	2,027	2,046	2,056	2,065	2,075
Dividend per share	—	—	4.67	—	—	—	3.86	—	—	—	3.92	—